Table 3.
Pretreatment evaluation
| Routine practice | Clinical trials specific | |
|---|---|---|
| Clinical evaluation | ||
| ECOG PS | Always | |
| Constitutive symptoms | Always | |
| Clinical examination | Always | |
| Cardiovascular comorbidities | Always | |
| Comedications | Always | |
| Biological standard tests | ||
| Complete blood count and reticulocyte count | Always | |
| LDH, haptoglobin and direct antiglobulin test | Always | |
| Serum creatinine level and glomerular filtration rate | Always | |
| Transaminases, bilirubin, GGT | Always | |
| LDH and beta-2 microglobulin | Always | |
| Serum protein electrophoresis | Always | |
| HIV, B and C hepatitis serology | Always | |
| Cryopreservation of blood cells (tumor library) | Desirable | Always |
| Genetics | ||
| Karyotype | Desirable | Always |
| FISH | ||
| 17p deletion | Always | |
| 11q deletion | Desirable | Always |
| 13q deletion | Desirable | Always |
| Trisomy 12 | Desirable | Always |
| IGHV mutational status | Always | |
| TP53 mutations by NGS | Always | |
| NGS of recurrent mutations | NGI | Desirable |
| Imaging | ||
| CT scan of chest, abdomen, and pelvis | Desirable | Recommended |
| Preventive measures | ||
| Vaccination against pneumococcus | Always | |
| Vaccination against influenza (yearly) | Always | |
| Vaccination against SARS-CoV-2 | Always | |
CT, computed tomography; GGT, gamma-glutamyl transferase; LDH, lactate dehydrogenase; NGI, not generally indicated.